Scientific Publication

Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations

author(s) Burger, D.. - Kiechel, J.R.. - Lallemant, M.. - Bouazza, N.. - Capparelli, E.V.. - Fauchet, F.. - Foissac, F.. - Treluyer, J.M.. - Urien, S.
from UK Foreign, Commonwealth & Development Office (FCDO)
permalink open
themes
citation

Bouazza, N.; Foissac, F.; Fauchet, F.; Burger, D.; Kiechel, J.R.; Treluyer, J.M.; Capparelli, E.V.; Lallemant, M.; Urien, S. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Antiviral Therapy (2014) : (DOI: 10.3851/IMP2876)

Publications and datasets provided via GARDIAN

Abstract

Lopinavir/ritonavir (LPV/r) is available in a liquid formulation far from ideal for treatment of children in resource poor settings. Flexible, low-cost, solid, fixed-dose oral combinations (FDC) of LPV/r with nucleoside reverse transcriptase inhibitors (NRTI) (LPV/ABC/3TC and LPV/ZDV/3TC) is needed to improve both management and adherence of children. This work was aimed to develop appropriate drug ratios and dosing for each FDCs

Open original